TNFRSF9 and head and neck squamous cell carcinoma: The results demonstrate that high levels of circulating CD137+ T cells are correlated with (R/M) HNSCC patients’ response to pembrolizumab treatment (p = 0.03) (Figure 1A; gating strategies in Figure S1A).